139 related articles for article (PubMed ID: 9105409)
41. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
Meng Q; Su T; O'Neill JP; Walker VE
Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
[TBL] [Abstract][Full Text] [Related]
42. Synergistic antiproliferative effect of interferons and azidothymidine on HL60 cells.
Nakae H; Asada S
Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):821-2. PubMed ID: 1377102
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts.
Houghton JA; Cheshire PJ; Morton CL; Stewart CF
Clin Cancer Res; 1995 Jan; 1(1):33-40. PubMed ID: 9815884
[TBL] [Abstract][Full Text] [Related]
44. Effects of 3'-azido-3'-deoxythymidine metabolites on simian virus 40 origin-dependent replication and heteroduplex repair in HeLa cell extracts.
Bebenek K; Thomas DC; Roberts JD; Eckstein F; Kunkel TA
Mol Pharmacol; 1993 Jan; 43(1):57-63. PubMed ID: 8380884
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines.
Majewski S; Szmurlo A; Marczak M; Jablonska S; Bollag W
Int J Cancer; 1994 Apr; 57(1):81-5. PubMed ID: 7512078
[TBL] [Abstract][Full Text] [Related]
46. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells.
Scanlon KJ; Funato T; Pezeshki B; Tone T; Sowers LC
Cancer Commun; 1990; 2(10):339-43. PubMed ID: 1698426
[TBL] [Abstract][Full Text] [Related]
47. Incorporation of 3'-azido-3'-deoxythymidine into cellular DNA and its removal in a human leukemic cell line.
Vazquez-Padua MA; Starnes MC; Cheng YC
Cancer Commun; 1990; 2(1):55-62. PubMed ID: 2369551
[TBL] [Abstract][Full Text] [Related]
48. Mutants from V79 fibroblasts exhibiting hypersensitivity to aphidicolin and 3'-azido-3'-deoxythymidine.
Liu PK; Norwood TH
Somat Cell Mol Genet; 1991 Jan; 17(1):1-13. PubMed ID: 1900132
[TBL] [Abstract][Full Text] [Related]
49. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells.
Olivero OA; Tejera AM; Fernandez JJ; Taylor BJ; Das S; Divi RL; Poirier MC
Mutagenesis; 2005 Mar; 20(2):139-46. PubMed ID: 15784690
[TBL] [Abstract][Full Text] [Related]
50. 3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.
Lynx MD; McKee EE
Biochem Pharmacol; 2006 Jul; 72(2):239-43. PubMed ID: 16720018
[TBL] [Abstract][Full Text] [Related]
51. Comparative effects of 3'-azido-3'-deoxythymidine and its metabolite 3'-amino-3'-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells.
Weidner DA; Bridges EG; Cretton EM; Sommadossi JP
Mol Pharmacol; 1992 Feb; 41(2):252-8. PubMed ID: 1538705
[TBL] [Abstract][Full Text] [Related]
52. [Growth inhibition of melanoma cells by interferons in vitro. Similar antiproliferative effects of 100-1000 times lower concentrations of nIFN-beta in comparison with rIFN-alpha-2a].
Zouboulis C; Garbe C; Orfanos CE
Hautarzt; 1989 Feb; 40(2):65-9. PubMed ID: 2714987
[TBL] [Abstract][Full Text] [Related]
53. The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with delocalized lipophilic cations.
Modica-Napolitano JS; Nalbandian R; Kidd ME; Nalbandian A; Nguyen CC
Cancer Lett; 2003 Jul; 198(1):59-68. PubMed ID: 12893431
[TBL] [Abstract][Full Text] [Related]
54. XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells.
Wu Q; Beland FA; Chang CW; Fang JL
Toxicol Appl Pharmacol; 2011 Mar; 251(2):155-62. PubMed ID: 21192964
[TBL] [Abstract][Full Text] [Related]
55. Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).
Elwell LP; Ferone R; Freeman GA; Fyfe JA; Hill JA; Ray PH; Richards CA; Singer SC; Knick VB; Rideout JL
Antimicrob Agents Chemother; 1987 Feb; 31(2):274-80. PubMed ID: 3551832
[TBL] [Abstract][Full Text] [Related]
56. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
[TBL] [Abstract][Full Text] [Related]
57. Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine.
Findenig G; Mader RM; Fritzer-Szekeres M; Steger GG; Jaeger W; Szekeres T
Oncol Res; 1996; 8(5):189-96. PubMed ID: 8884811
[TBL] [Abstract][Full Text] [Related]
58. Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells.
Chen C; Zhang Y; Wang Y; Huang D; Xi Y; Qi Y
Anticancer Drugs; 2011 Jun; 22(5):435-43. PubMed ID: 21502917
[TBL] [Abstract][Full Text] [Related]
59. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
60. Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients.
Nokta M; Loh JP; Douidar SM; Ahmed AE; Pollard RB
J Interferon Res; 1991 Jun; 11(3):159-64. PubMed ID: 1919075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
